Notably, as with CK-18, CYP and UGT expression is also altered by a number of other forms of liver disease, making it unlikely that these markers will be able to distinguish NAFLD from other forms of liver pathology. Here, SLC35A2 is linked to metabolic dysfunction-associated steatotic liver disease.